Author of

• 10984

  +

  P1.22 - Poster Session 1 - Epidemiology, Etiology (ID 166)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Prevention & Epidemiology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10991

    +

    P1.22-007 - The prevalence of epidermal growth factor receptor (EGFR) mutation in non-small non-squamous lung cancer in UAE (a single institute experience in the middle east) (ID 2463)

    09:30 - 16:30  |  Author(s): M. Jaloudi
    • Abstract

    Background
    Epidermal growth factor receptor (EGFR) is a trans-membrane protein it belongs to the ErbB-family, its activity includes transmitting of growth factor signaling from the surface of cells into the cells and activates the enzyme tyrosine kinase, triggering reactions that cause the cells to grow and multiply. EGFR has an impact on malignant cells development in various tumors, affecting their proliferation, apoptosis, motility and angiogenesis. In NSCL cancer EGFR-protein mutations in exons 18–21 results in constant hyper-activation of downstream pro-survival signaling pathways, independent from any external receptor stimulation. Approximately 10% of US patients and 35% in East Asia patients show EGFR mutation of which, almost 90% of these mutations are exon 19 deletions or exon 21 l858r point mutations. EGFR has been identified as an important therapeutic target for the treatment. Purpose: To evaluate the prevalence of EGFR mutations in the diagnosed cases of NSCLC in our hospital, which deals with approximately 80% of lung cancer cases in UAE and to compare it with other geographic and ethnic groups.

    Methods
    Methods: A retrospective analysis of all non-small non-squamous lung ca cases that had EGFR testing was performed. LAB 21 in UK was used for the EGFR mutation testing. A total of 50 tumor blocks were sent to the laboratory. The test could not be performed on one case. Out of the remaining 49 patients, 13 (26%) were female and 36 (74%) were male. Open biopsy by either lymph node excision, pleuroscopy, open lung biopsy or craniotomy were the tissue source for the EGFR analysis in 23 patients while only 15 had enough tissue from one procedure (bronchoscopy or guided biopsy).

    Results
    Results: EGFR mutation was identified in 18/49 (37%) patients. of the 18 patient, who had EGFR mutation, 10 (56%) patients had exon 19 mutation, 6 (33%) patients had exon 21 deletion and 2 (11%) patient had double mutation. in those two patients with double mutation, one had mutation in exons 19 and 21 and the other had mutation in exons 18 and 20. No significant difference was observed in EGFR-mutations among the gender of patients, 35% in men and 38% in women. Analysis of ethnicity and prevalence of EGFR-mutation showed a significant difference between Arabs (15 of 32 / 46%) and non-Arabs (3 of 17 / 18%). in the Arabian cohort with EGFR mutations 8 out of 22 patients (36 %) had a smoking history and 7 out of 10 (70%) were documented as non (never)-smoker.

    Conclusion
    Conclusion: Local prevalence of EGFR mutation was found to be 37% among all the ethnic groups, which is in line with the incidence in Asian population but the Prevalence of EGFR mutations in Arabs was (46%). it is to be stressed here that testing for EGFR mutations should be considered for all patients with non-small non squamous cell lung cancer at diagnosis, regardless of clinical characteristics. This strategy can warrant the prompt use of EGFR tyrosine kinase inhibitors to promote the practice of personalized medicine.